Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel
Jann N. Sarkaria(Mayo Clinic), C. David James(Northwestern University), Wenting Wu(Wenzhou Institute of Industrial Science), Evanthia Galanis(The University of Texas at San Antonio Health Science Center), Brett L. Carlson(University of California, San Francisco), Caterina Giannini(Mayo Clinic), Patrick T. Grogan, Mark A. Schroeder(MACOM (United States)), Lin Yang(Mayo Clinic), Gaspar J. Kitange(University of California, San Francisco), Eduard B. Dinca(Mayo Clinic)
Cited by 203
Related Papers
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783
Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
|Journal of Clinical Oncology|2005|695
Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
|Neuro-Oncology|2015|665